# US 12,161,612 B2 · Methods and compositions for reducing symptoms of Parkinson's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,161,612 B2
- Document ID: US12161612B2
- Status: Granted
- Kind: B2
- Application number: 18/636,148
- Filed: 2024-04-15
- Published: 2024-10-17
- Granted: 2024-12-10
- Earliest claimed: 2023-04-14
- Assignees: NeuroDerm, Ltd.
- Applicants: NeuroDerm, Ltd.
- Inventors: Liat Adar; Nelson Felix Lopes; Laurence Salin; Tamar Yardeni; Nissim Sasson; Sheila Oren; Hikari Yarita; Mikio Himizu; Natalia Vostokova
- Web page: https://patentgrep.com/patent/US12161612B2

## CPC

- A61K 31/195: having an amino group
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/20: Hypnotics; Sedatives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.

## Claims

### Claim 1

A method of treating a patient with Parkinson's disease, the method comprising subcutaneously administering to the patient, substantially continuously for about 24 hours/day and for about 2 to 3 consecutive days, a pharmaceutically acceptable liquid composition comprising levodopa and carbidopa in a ratio of about 8:1 w/w, and further comprising arginine,
wherein by the third consecutive day the administration results in the patient having at least one of:
an increase from baseline of at least about 0.3 to 3.5 hours in daily Good ON-time,
a reduction from baseline of at least about 0.3 to 2.5 hours in daily ON-time with moderate-severe dyskinesia,
a reduction from baseline of at least 0.1 to 2.0 hours in daily OFF-time,
an increase from baseline of at least about 0.1 to 3.5 hours in daily ON-time without dyskinesia,
a reduction from baseline of at least 0.1 to 3.2 hours in total daily troublesome dyskinesia,
an improvement from baseline in motor experiences of daily living, as assessed by the Movement Disorder Society-Sponsored revision of Unified Parkinson's Disease Rating Scale Part III (UPDRS Part III) score, resulting in a reduction from baseline of about 2 to 13 points in the UPDRS Part III score,
or any combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable liquid composition is administered subcutaneously to the patient via a device comprising a control station, a reusable part and a disposable part.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable liquid composition comprises 7.5 mg/mL carbidopa and 60 mg/mL levodopa.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable liquid composition is administered to deliver about 720 mg of levodopa and about 90 mg of carbidopa to the patient over the course of about 24 hours.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable liquid composition is administered subcutaneously to the patient at a first flow rate and a second flow rate over the course of 24 hours, wherein a first flow rate is a high activity rate for day hours and the second flow rate is a low activity rate for night hours.

### Claim 6 (depends on 5)

The method of claim 5, wherein the low activity night rate is administered for about 6 hours and the high activity day rate is administered for about 18 hours.

### Claim 7 (depends on 5)

The method of claim 5, wherein the low activity night rate is about 0.08 mL/hour and wherein the high activity day rate is about 0.64 mL/hour, about 0.59 mL/hour, about 0.55 mL/hour, about 0.50 mL/hour, about 0.45 mL/hour, about 0.41 mL/hour, about 0.36 mL/hour, or about 0.32 mL/hour.

### Claim 8 (depends on 5)

The method of claim 5, wherein after about 5 hours of administration at the first flow rate, the patient is fully ON.

### Claim 9 (depends on 1)

The method of claim 1, wherein the patient has an improvement from baseline after two days of treatment in quality of sleep.

### Claim 10

A method of treating a patient with Parkinson's disease, the method comprising subcutaneously administering to the patient, substantially continuously for about 24 hours/day and for about 2 to 3 consecutive days, a pharmaceutically acceptable liquid composition comprising levodopa, carbidopa, and arginine,
wherein the pharmaceutically acceptable liquid composition comprises about 60 mg/ml levodopa and 7.5 mg/mL carbidopa, and wherein the pharmaceutically acceptable liquid composition is administered to deliver about 720 mg of levodopa and about 90 mg of carbidopa to the patient over the course of about 24 hours,
wherein by the third consecutive day the administration results in the patient having at least one of:
an increase from baseline of at least about 0.3 to 3.5 hours in daily Good ON-time,
a reduction from baseline of at least about 0.3 to 2.5 hours in daily ON-time with moderate-severe dyskinesia,
a reduction from baseline of at least 0.1 to 2.0 hours in daily Off time,
an increase from baseline of at least about 0.1 to 3.5 hours in daily ON-time without dyskinesia,
a reduction from baseline of at least 0.1 to 3.2 hours in total daily troublesome dyskinesia,
a reduction from baseline of about 2 to 13 points in UPDRS Part III scores,
or any combination thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the method further comprises administering to the patient, before or during the subcutaneous infusion time course, at least one pharmaceutically acceptable oral composition comprising levodopa.

### Claim 12 (depends on 10)

The method of claim 10, wherein the pharmaceutically acceptable liquid composition is administered subcutaneously to the patient via a device comprising a control station, a reusable part and a disposable part.

### Claim 13 (depends on 10)

The method of claim 10, wherein the pharmaceutically acceptable liquid composition is administered subcutaneously to the patient at a first flow rate and a second flow rate over the course of 24 hours, wherein a first flow rate is a high activity rate for day hours and the second flow rate is a low activity rate for night hours.

### Claim 14 (depends on 10)

The method of claim 10, wherein the low activity night rate is administered for about 6 hours or about 8 hours and the high activity day rate is administered for about 18 hours or about 16 hours, respectively.

### Claim 15 (depends on 14)

The method of claim 14, wherein the low activity night rate is about 0.08 mL/hour and wherein the high activity day rate is about 0.64 mL/hour, about 0.59 mL/hour, about 0.55 mL/hour, about 0.50 mL/hour, about 0.45 mL/hour, about 0.41 mL/hour, about 0.36 mL/hour, or about 0.32 mL/hour.

### Claim 16 (depends on 14)

The method of claim 14, wherein after about 5 hours of administration at the first flow rate, the patient is fully ON.

### Claim 17 (depends on 10)

The method of claim 10, wherein the patient has an improvement from baseline after two days of treatment in quality of sleep.

### Claim 18

A method of increasing Good ON-time in a patient with Parkinson's disease, the method comprising
subcutaneously administering to the patient, substantially continuously for about 24 hours/day for about 2 to 3 consecutive days, a pharmaceutically acceptable liquid composition comprising levodopa and carbidopa, in a ratio of about 8:1 w/w, and further comprising arginine,
wherein by the third consecutive day the administration results in an increase from baseline of at least about 0.3 to 3.5 hours in daily Good ON-time.

### Claim 19 (depends on 18)

The method of claim 18, wherein the administration results in an increase from baseline of about 1.8 hours in daily Good ON-time.

### Claim 20 (depends on 18)

The method of claim 18, wherein the pharmaceutically acceptable liquid composition is administered subcutaneously to the patient via a device comprising a control station, a reusable part and a disposable part.

### Claim 21 (depends on 18)

The method of claim 18, wherein the pharmaceutically acceptable liquid composition comprises 7.5 mg/mL carbidopa and 60 mg/mL levodopa.

### Claim 22 (depends on 18)

The method of claim 18, wherein the pharmaceutically acceptable liquid composition is administered to deliver about 720 mg of levodopa and about 90 mg of carbidopa to the patient over the course of about 24 hours.

### Claim 23 (depends on 18)

The method of claim 18, wherein the method further comprises administering to the patient, before or during the subcutaneous infusion time course, at least one pharmaceutically acceptable oral composition comprising levodopa.

### Claim 24 (depends on 18)

The method of claim 18, wherein the pharmaceutically acceptable liquid composition is administered subcutaneously to the patient at a first flow rate and a second flow rate over the course of 24 hours, wherein a first flow rate is a high activity rate for day hours and the second flow rate is a low activity rate for night hours.

### Claim 25 (depends on 24)

The method of claim 24, wherein the low activity night rate is administered for about 6 hours and the high activity day rate is administered for about 18 hours.

### Claim 26 (depends on 24)

The method of claim 24, wherein the low activity night rate is about 0.08 mL/hour.

### Claim 27 (depends on 24)

The method of claim 24, wherein the high activity day rate is about 0.64 mL/hour, about 0.59 mL/hour, about 0.55 mL/hour, about 0.50 mL/hour, about 0.45 mL/hour, about 0.41 mL/hour, about 0.36 mL/hour, or about 0.32 mL/hour.

### Claim 28 (depends on 24)

The method of claim 24, wherein after about 5 hours of administration at the first flow rate, the patient is fully ON.

### Claim 29 (depends on 18)

The method of claim 18, wherein after two days of treatment, the patient has an improvement from baseline in quality of sleep.
